NEKTAR 214: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

February 19, 2019
https://clinicaltrials.gov/ct2/results?id=NCT02983045
Cancer - Renal Cell
Principal Investigator: Ding Wang, MD
Cancer, Renal Cell, Renal Cell Carcinoma, Renal Cancer, NSCL, urothelial, Solid Tumors, Advanced, Select, Metastatic, Malignancies, Phase I, Phase 1
Open